HBK Investments L P increased its holdings in Allergan plc (NYSE:AGN) by 2,064.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 93,057 shares of the company’s stock after buying an additional 88,757 shares during the period. HBK Investments L P’s holdings in Allergan were worth $15,222,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Edgewood Management LLC lifted its stake in Allergan by 24.3% in the 3rd quarter. Edgewood Management LLC now owns 4,445,924 shares of the company’s stock worth $911,192,000 after purchasing an additional 869,248 shares in the last quarter. Geode Capital Management LLC lifted its stake in Allergan by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 3,422,365 shares of the company’s stock worth $558,625,000 after purchasing an additional 72,303 shares in the last quarter. Baupost Group LLC MA lifted its stake in Allergan by 21.9% in the 3rd quarter. Baupost Group LLC MA now owns 2,964,203 shares of the company’s stock worth $607,513,000 after purchasing an additional 531,600 shares in the last quarter. Parnassus Investments CA lifted its stake in Allergan by 20.4% in the 4th quarter. Parnassus Investments CA now owns 2,161,833 shares of the company’s stock worth $353,633,000 after purchasing an additional 365,914 shares in the last quarter. Finally, Epoch Investment Partners Inc. lifted its stake in Allergan by 1.0% in the 3rd quarter. Epoch Investment Partners Inc. now owns 1,805,608 shares of the company’s stock worth $370,060,000 after purchasing an additional 17,068 shares in the last quarter. 78.40% of the stock is owned by institutional investors.
AGN has been the topic of several recent analyst reports. Royal Bank of Canada set a $218.00 target price on shares of Allergan and gave the stock a “buy” rating in a research note on Thursday, January 4th. Credit Suisse Group set a $214.00 target price on shares of Allergan and gave the stock a “buy” rating in a research note on Tuesday, December 19th. They noted that the move was a valuation call. Vetr cut shares of Allergan from a “strong-buy” rating to a “buy” rating and set a $187.73 price objective on the stock. in a research report on Wednesday, December 6th. Morgan Stanley set a $200.00 price objective on shares of Allergan and gave the company a “buy” rating in a research report on Wednesday, December 6th. Finally, Wells Fargo & Co restated a “buy” rating on shares of Allergan in a research report on Wednesday, December 6th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $225.03.
Allergan (NYSE:AGN) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.74 by $0.12. The business had revenue of $4.33 billion for the quarter, compared to analyst estimates of $4.28 billion. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.43%. The company’s revenue was up 12.0% on a year-over-year basis. During the same quarter last year, the firm earned $3.90 EPS. equities analysts expect that Allergan plc will post 15.58 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th will be issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.82%. The ex-dividend date is Tuesday, February 27th. This is a positive change from Allergan’s previous quarterly dividend of $0.70. Allergan’s dividend payout ratio (DPR) is -24.02%.
In other news, CEO Brent L. Saunders purchased 3,300 shares of the business’s stock in a transaction on Thursday, March 8th. The shares were acquired at an average price of $152.53 per share, with a total value of $503,349.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Matthew M. Walsh purchased 1,000 shares of the business’s stock in a transaction on Thursday, March 8th. The stock was purchased at an average cost of $153.96 per share, for a total transaction of $153,960.00. The disclosure for this purchase can be found here. In the last three months, insiders acquired 7,200 shares of company stock worth $1,108,267. Insiders own 0.36% of the company’s stock.
TRADEMARK VIOLATION WARNING: “HBK Investments L P Has $15.22 Million Position in Allergan plc (AGN)” was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/03/13/hbk-investments-l-p-has-15-22-million-position-in-allergan-plc-agn.html.
Allergan Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.